Effect of bosentan on macro- and microvascular function in patients with type 2 diabetes - BANDY

John Pernow0 个研究点开始时间: 2007年7月3日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1. Diabetes mellitus type 2 of >2 years duration
•2. Albuminuria
•Patients are classified as having diabetes mellitus if fasting blood glucose exceeded 6.0 mmol/l (on at least on two occasions) or blood glucose concentration is >11.0 mmol/l two h after an oral glucose loading (75 g). Albuminuria is defined as urine albumin concentration >20 microg/l or >30 microg/12h
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Age >80 years
•2. Myocardial infarction/unstable angina within three months prior to randomisation
•3. Decompensated congestive heart failure
•4. Changes in dosage of any vasodilator drugs during the preceding six weeks
•5. Childbearing potential
•6. Impaired hepatic function (2 times upper normal limit of ASAT and ALAT)
•7. Ongoing treatment with glibenklamide, cyklosporin or warfarin
•8. Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol
•9. Participant in an ongoing study
•10. Unwillingness to participate following oral and written information

发起方

John Pernow